Cothera Bioscience, the parent company of Percans Oncology, has announced that on March 8, 2022, it received approval from the National Medical Products Administration (NMPA) to conduct a Phase 2 clinical trial to test its targeted MYC mutation inhibitor PC-002 as a first-line or second-line treatment for drug-resistant or relapsed high-grade B-cell lymphoma (HGBCL). The NMPA completed its review of the project in just 45 working days, demonstrating the strong support of regulatory authorities for innovative drugs.
PC-002, the core product of Cothera Bioscience, is a first-in-class small molecule drug targeting MYC-mutated tumors. With a unique mechanism of action (MOA), PC-002 selectively induces MYC protein degradation and cell apoptosis in MYC-dependent tumors. With more than 50% of human cancers showing increased expression, MYC is regarded as one of the most important yet “undruggable” cancer targets. Via its unique mechanism, PC-002 selectively kills tumor cells with MYC mutation and may potentially target multiple indications in cancers.